Genomic Basis of Anti-Inflammatory Properties of Boswellia Extract

Genomics, Proteomics, and Metabolomics in Nutraceuticals and Functional Foods

Volumn , Issue , 2010, Pages 155-174

  Trimurtulu, Golakoti ^a   Sen, Chandan K ^b   Krishnaraju, Alluri V ^a   Sengupta, Krishanu ^a  

^a Unit I   (India)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Gene chip probe array analysis; Genetic Basis for Efficacy of BE 30; Genetic Basis of Anti Inflammatory Properties of Boswellia Extract; Human Clinical Studies Validate Gene Chip Studies; Lequesne functional index (LFI); TNF induced MMP 3 protein expression; Western Ontario and McMaster Universities (WOMAC)

Indexed keywords

EID: 84886552475     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780813821474.ch11     Document Type: Chapter

References (41)

1. Simmons, D. L., Xie, W., Chipman, J. G., Evett, G. E., Multiple cyclooxygenases: cloning of a mitogen inducible form. In: J. M. Bailey (ed.), Prostaglandins, Leukotrienes, Lipoxins, and PAF. New York: Plenum, pp. 67-78, 1992.
2. Smith, W. L., Dewitt, D. L., Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996, 62, 167-215.
3. Yamamoto, S., Mammalian lipoxygenases: molecular structures and functions. Biochim Biophys Acta 1992, 1128, 117-131.
4. Ethan, B., Heather, B., Theresa, D. H., Ivo, F., et al., Boswellia: An evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother 2004, 4, 63-83.
5. Chatterjee, G. K., Pal, S. D. Indian Drugs 1984, 21, 431.
6. Ammon, H. P., Mack, T., Singh, G. B., Safayhi, H., Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata. Planta Med 1991, 57, 203-207.
7. Singh, G. B., Atal, C. K., Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 1986, 18, 407-412.
8. Ammon, H. P. T., Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases. Wien Med Wochenschr 2002, 152, 373-378.
9. Kimmatkar, N., Thawani, V., Hingorani, L., Khiyani, R., Efficacy and tolerability of Boswellia serrata in treatment of osteoartritis of knee-A randomized double blind placebo controlled trial. Phytomedicine 2003, 10, 3-7.
10. Gupta, I., Parihar, A., Malhotra, P., Gupta, S., et al., Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001, 67, 391-395.
11. Gupta, I., Parihar, A., Malhotra, P., Singh, G. B., et al., Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997, 2, 37-43.
12. Gerhardt, H., Seifert, F., Buvari, P., Vogelsang, H., et al., Therapy of active Crohn disease with Boswellia serrata extract H15. Z Gastroenterol 2001, 39, 11-17.
13. Gupta, I., Gupta, V., Parihar, A., Gupta, S., et al., Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 1998, 3, 511-514.
14. Safayhi, H., Sailer, E. R., Anti-inflammatory actions of pentacyclic triterpenes. Planta Med 1997, 63, 487-493.
15. Pardhy, R. S., Bhattacharya, S. C., B-boswellic acid, acetyl-b-boswellic acid, acetyl-11-keto-b-boswellic acid & 11-keto-b-boswellic acid and four pentacyclic triterpene acids from the resin of s Roxb. Indian J Chem 1978, 16B, 176-178.
16. Safayhi, H., Rall, B., Sailer, E. R., Ammon, H. P. T., Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther 1997, 281, 460-463.
17. Poff, C. D., Balazy, M., Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer. Curr Drug Targets Inflamm Allergy 2004, 3, 19-33.
18. Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M. I., et al., Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992, 26, 1143-1146.
19. Sailer, E. R., Subramanian, L. R., Rall, B., Hoernlein, R. F., et al., Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 1996, 117, 615-618.
20. Sailer, E. R., Schweizer, S., Boden, S. E., Ammon, H. P. T., et al., Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem 1998, 256, 364-368.
21. Safayhi, H., Sailer, E. R., Ammon, H. P. T., Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol 1995, 47, 1212-1216.
22. Roy, S., Khanna, S., Shah, H., Rink, C., et al., Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells. DNA Cell Biol 2005, 24(4), 244-255.
23. Roy, S., Khanna, S., Krishnaraju, A.V., Subbaraju, G. V., et al., Regulation of vascular response to inflammation: inducible matrix metalloprotenase-3 expression in human microvascular endothelial cells is sensitive to anti-inflammatory Boswellia. Antioxid Redox Signal 2006, 8 (3&4), 653-660.
24. Lalithakumari, K., Krishnaraju, A. V., Subbaraju, G. V., Yasmin, T., et al., Safety and toxicological evaluation of a novel, standardized 3-acetyl-11-keto-ß-boswellic acid (AKBA)-enriched Boswellia serrata extract (5-Loxin). Toxicol Mech Methods 2006, 16, 199-226.
25. Sengupta, K., Alluri, K. V., Satish, A. R., Mishra, S., et al., Double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin R for treatment of osteoarthritis of the knee. Arthritis Res Ther 2008, 10(4), R85-R96.
26. Warren, J. S., Ward, P. A., Johnson, K. J., Tumor necrosis factor: A plurifunctional mediator of acute inflammation. Modern Pathol 1988, 1, 242-247
27. Strieter, R. M., Kunkel, S. L., Bone, R. C., Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993, 21, S447-S463.
28. Sullivan, K. E., Regulation of inflammation. Immunol Res 2003, 27, 529-538.
29. Pober, J. S., Endothelial activation: Untracellular signaling pathways. Arthritis Res 2002, 4(3), S109-S116.
30. Li, C., Wong, W. H., Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci 2001, 98, 31-36.
31. Albelda, S. M., Smith, C. W., Ward, P. A., Adhesion molecules and inflammatory injury. FASEB 1994, 8, 504-512.
32. Barreiro, O., Yáñez-Mó, M., Serrador, J. M., Montoya, M. C., et al., Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol 2002, 157(7), 1233-1245.
33. Massova, I., Kotra, L. P., Fridman, R., Mobashery, S., Matrix metalloprotenases: Structures, evolution, and diversification. FASEB Journal 1998, 12, 1075-1095.
34. Herouy, Y., The role of matrix metalloproteinases (MMPs) and their inhibitors in venous leg ulcer healing. Phlebolymphology 2004, 44, 231-243.
35. Sengupta, K., Tummala, T., Golakoti, T., 30% 3-O-acetyl-11-keto-ß-boswellic acid inhibits phorbol-myristate acetate stimulated matrix metalloproteinase-3 in A2058 human melanoma cells. Study no. LI/CMB/MMP-3/02/08. Submitted to the archival files, Laila Impex R&D Center, 2008.
36. Indrani, B. K., Bacterial reverse mutation test with 5-Loxin. Study No. 4477/05, Toxicology Department, Advinus Therapeutics Private Limited, Post Box No. 5813, Plot Nos 21 & 22, Peenya Industrial Area, Phase II, Bangalore, India 560 058, 2006.
37. Chang, J-T., Micronucleus assay in mice 5-Loxin. Study numbers MN00075 and CA00094, Center of Toxicology and Preclinical Sciences, Development Center for Biotechnology, 101, Lane 169, Kangning St, Xizhi City, Taipei County 221, Taiwan, 2007.
38. Takahashi, M., Naito, K., Abe, M., Sawada, T., et al., Relationship between radiographic grading of osteoarthritis and the biochemical markers for arthritis in knee osteoarthritis. Arthritis Res Ther 2004, 6(3), R208-R212.
39. Bellamy, N., Buchnan, W. W., Goldsmith, C. H., Campbell, J., et al., Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15, 1833-1840.
40. Lequesne, M. G., Mery, C., Samson, M., Gerard, P., Indexes of severity for osteoarthritis of the hip and knee validation-value in comparison with other assessment tests. Scand J Rheumatol 1987, 65, 85-89.
41. Chapman, C. R., Casey, K. L., Dubner, R., Foley, K. M., et al., Pain measurement: an overview. Pain 1985, 22, 1-31.